Company News Sun Pharma Receives Form 483 Due To Out-of-Spec Products March 27, 2019 The India-based manufacturer receives a Form 483 from the US FDA after the agency noted the company failed to thoroughly review discrepancies. – Medical Buyer Bureau Related Topics: Up Next Sun Pharma Gets Observation From USFDA For Baska Plant Don't Miss Lupin, YL Biologics Get Nod To Market Rheumatoid Arthritis Drug
